Daiwa Securities Group Inc. Lowers Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Daiwa Securities Group Inc. reduced its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 7.4% during the third quarter, HoldingsChannel.com reports. The firm owned 17,942 shares of the medical instruments supplier’s stock after selling 1,430 shares during the quarter. Daiwa Securities Group Inc.’s holdings in ICU Medical were worth $3,269,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. SG Americas Securities LLC grew its stake in shares of ICU Medical by 441.7% in the second quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock worth $691,000 after acquiring an additional 4,744 shares during the last quarter. LMR Partners LLP purchased a new stake in ICU Medical during the 3rd quarter valued at about $3,884,000. Vanguard Group Inc. increased its stake in ICU Medical by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after purchasing an additional 11,991 shares in the last quarter. Savant Capital LLC purchased a new position in ICU Medical in the second quarter worth about $431,000. Finally, Boston Partners bought a new position in shares of ICU Medical in the first quarter worth approximately $790,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Raymond James boosted their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. KeyCorp boosted their price target on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Jefferies Financial Group assumed coverage on shares of ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Stock Up 1.3 %

ICUI stock opened at $159.75 on Thursday. The business’s 50-day moving average is $175.61 and its two-hundred day moving average is $146.51. The company has a market cap of $3.91 billion, a price-to-earnings ratio of -34.62 and a beta of 0.66. ICU Medical, Inc. has a fifty-two week low of $83.26 and a fifty-two week high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,096,771.78. This represents a 10.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director David C. Greenberg sold 972 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the transaction, the director now directly owns 5,037 shares in the company, valued at approximately $796,400.07. This represents a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,866 shares of company stock worth $7,284,854 in the last quarter. Company insiders own 6.70% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.